Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Top Cited Papers
- 24 January 2017
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 106, 1-7
- https://doi.org/10.1016/j.lungcan.2017.01.013
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-AnalysisJNCI Journal of the National Cancer Institute, 2014
- Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortJournal of Translational Medicine, 2014
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancerCritical Reviews in Oncology/Hematology, 2013
- Comparative Effectiveness Research in Oncology Methodology: Observational DataJournal of Clinical Oncology, 2012
- A framework for understanding cancer comparative effectiveness research data needsJournal of Clinical Epidemiology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain MetastasesJournal of Clinical Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsThe New England Journal of Medicine, 1999